EMA/178290/2017

European Medicines Agency decision

P/0097/2017

of 11 April 2017

on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human N-acetylglucosaminidase (rhNAGLU) (EMEA-001653-PIP01-14-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0097/2017

of 11 April 2017

on the acceptance of a modification of an agreed paediatric investigation plan for recombinant human N-acetylglucosaminidase (rhNAGLU) (EMEA-001653-PIP01-14-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0082/2015 issued on 10 April 2015,

Having regard to the application submitted by Alexion Europe SAS on 12 December 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 February 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for recombinant human N-acetylglucosaminidase (rhNAGLU), concentrate for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Alexion Europe SAS, 1-15 avenue Edouard Belin, 92500 - Rueil-Malmaison, France.

EMA/PDCO/861764/2016 Corr
London, 24 February 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001653-PIP01-14-M02

Scope of the application

Active substance(s):

Recombinant human N-acetylglucosaminidase (rhNAGLU)

Condition(s):

Treatment of mucopolysaccharidosis IIIB (Sanfilippo B)

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Alexion Europe SAS

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Alexion Europe SAS submitted to the European Medicines Agency on 12 December 2016 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/0082/2015 issued on 10 April 2015.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2017.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of mucopolysaccharidosis IIIB (Sanfilippo B)

2.1.1. Indication(s) targeted by the PIP

Treatment of mucopolysaccharidosis IIIB (Sanfilippo B)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of higher concentration formulation resulting in administration volumes appropriate to the paediatric population.
Non-clinical studies	1	**Study 2** Intravenous infusion study of rhNAGLU in the juvenile cynomolgus monkey
Clinical studies	5	**Study 3 NGLU-CL02** Open-label, dose escalation study to evaluate safety, tolerability, PK, PD and activity of recombinant human N-acetylglucosaminidase (rhNAGLU) administered intravenously. **Study 4 NGLU-CL06** Removed in Modification EMEA-001653-PIP01-14-M02. **Study 5 NGLU-CL03** Randomized, double-blind, placebo-controlled study to evaluate efficacy of recombinant human N-acetylglucosaminidase (rhNAGLU) in children from birth to less than 6 years of age for the treatment of

		mucopolysaccharidosis IIIB (Sanfilippo B). **Study 6** Randomized, double-blind, placebo-controlled study to evaluate efficacy of recombinant human N-acetylglucosaminidase (rhNAGLU) in children from 6 to less than 18 years of age for the treatment of mucopolysaccharidosis IIIB (MPS IIIB; Sanfilippo B). **Study 7 NGLU-NH01** Retrospective chart review of deceased MPS IIIB patients to generate data to evaluate the clinical characteristics and course of disease progression of MPS IIIB. **Study 8 NGLU-NH02** Observational study to describe the clinical and biochemical characteristics and course of disease progression in patients with MPS IIIB.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2022
Deferral for one or more measures contained in the paediatric investigation plan:	No